TABLE 1.
The Clinical-Pathological Characteristics of Meningioma Patients Included in the Data Set at All Phases of the Study
| Screening phase | Training phase | Validation phase | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort | n | 38 | 59 | 172 | |||||||||
| MRR− | MRR+ | P value | Totala | MRR− | MRR+ | P value | Totala | MRR− | MRR+ | P value | Totala | ||
| Female/male | n (%) | 13/2 (86.7/13.3) | 7/4 (63.6/36.4) | .348 | 28/10 (73.7/26.3) | 21/4 (84.0/16.0) | 10/10 (50.0/50.0) | .034 | 40/19 (67.8/32.2) | 47/12 (79.7/20.3) | 19/18 (51.4/48.6) | .007 | 115/57 (66.9-33.1) |
| Age (yr) | Median (IQR) | 54 (43-61) | 53 (45-61) | .812 | 54 (43-64) | 51 (43-61) | 48 (41-61) | .912 | 50 (43-60) | 56 (45-62) | 52 (42-64) | .596 | 56 (45-65) |
| WHO grade I/II/III | n (%) | 9/2/3 (64.3/14.3/21.4) | 3/5/3 (27.3/45.5/27.3) | .128 | 14/12/11 (37.8/32.4/29.7) | 24/1/0 (96.0/4.0/0.0) | 16/4/0 (80.0/20.0/0.0) | .155 | 51/8/0 (86.4/13.6/0.0) | 51/3/4 (87.9/5.2/6.9) | 21/11/4 (58.3/30.6/11.1) | .001 | 125/31/14 (73.5/18.2/8.2) |
| Convexity/skull base meningioma | n (%) | 6/9 (40.0/60.0) | 7/4 (63.6/36.4) | .427 | 17/21 (44.7/55.3) | 8/17 (32.0/68.0) | 8/12 (40.0/60.0) | .807 | 23/36 (39.0/61.0) | 20/39 (33.9/66.1) | 18/19 (48.6/51.4) | .221 | 72/100 (41.9/58.1) |
| Simpson grade I-III/>III | n (%) | 12/3 (80.0/20.0) | 8/3 (72.7/27.3) | 1 | 30/7 (81.1/18.9) | 21/2 (91.3/8.7) | 9/11 (45.0/55.0) | .003 | 40/17 (70.2/29.8) | 47/8 (85.5/14.5) | 20/17 (54.1/45.9) | .002 | 127/39 (76.5/23.5) |
| Add-on radiotherapy (yes/no) | n (%) | 4/11 (26.7/73.3) | 6/5 (54.5/45.5) | .228 | 13/25 (34.2/65.8) | 3/22 (12.0/88.0) | 12/8 (60.0-40.0) | .002 | 15/44 (25.4/74.6) | 10/49 (16.9/83.1) | 22/15 (59.5/40.5) | <.001 | 36/136 (20.9/79.1) |
| Follow-up (mo) | Median (IQR) | 149.3 (113.7-198.1) | 99.8 (87.6-123.4) | .005 | 100.9 (66.8-144.7) | 161.2 (124.4-202.2) | 138.3 (102.3-191.8) | .233 | 124.4 (85.5-181.5) | 146.2 (124.5-202.6) | 120.0 (87.3-173.4) | .004 | 95.7 (65.8-145.7) |
| Time to relapseb | % | – | – | – | 64.5 ± 8.8 | – | – | – | 61.3 ± 6.9 | – | – | – | 72.5 ± 4.0 |
IQR, interquartile range (first quartile through third quartile); MRR+, patients with meningiomas with evidence of radiographic recurrence up to 8 yr after surgery; MRR−, patients with meningiomas without evidence of radiographic recurrence up to 8 yr after surgery; WHO, World Health Organization.
aIncluding patients with follow-up <8 yr without recurrence.
bKaplan-Meier estimate of survival at the time of 8 yr after surgery: 8-yr survival ± standard error.